{
    "id": "0d97baee-944e-fd5f-b960-04e367dc5983",
    "indications": "fesoterodine fumarate extended-release indicated treatment : • overactive bladder ( oab ) adults symptoms urge urinary incontinence , urgency , frequency . ( 1.1 ) • neurogenic detrusor overactivity ( ndo ) pediatric patients 6 years age older weighing greater 25 kg . ( 1.2 )",
    "contraindications": "• oab adults : recommended starting 4 mg orally daily . based upon individual response tolerability , increase maximum 8 mg daily . ( 2.1 ) • ndo pediatric patients 6 years older : pediatric patients weighing greater 25 kg 35 kg : recommended 4 mg orally daily . needed , may increased 8 mg orally daily . ( 2.2 ) pediatric patients weighing greater 35 kg : recommended starting 4 mg orally daily . one week , increase 8 mg orally daily . ( 2.2 ) • adult pediatric patients renal impairment : refer full prescribing information recommended . ( 2.3 , 2.4 ) • modifications due strong cyp3a4 inhibitors : refer full prescribing information recommended . ( 2.5 ) • : swallow whole liquid . chew , divide , crush . take without food . ( 2.6 )",
    "warningsAndPrecautions": "fesoterodine fumarate extended-release tablets , 4 mg light blue colored , oval shaped , biconvex , film-coated , debossed ‘ ’ one side 'fs ' side supplied bottles 30 's , 90 ’ . bottles 30 ndc 43598-247-30 bottles 90 ndc 43598-247-90 fesoterodine fumarate extended-release tablets , 8 mg blue colored , oval shaped , biconvex , film-coated , debossed ‘ ’ one side ‘ ft ’ side supplied bottles 30 's , 90 ’ . bottles 30 ndc 43598-248-30 bottles 90 ndc 43598-248-90 store fesoterodine fumarate extended-release tablets , 20º 25°c ( 68º 77°f ) [ usp controlled room temperature ] . protect moisture .",
    "adverseReactions": "fesoterodine fumarate extended-release tablets contraindicated patients following , known suspected hypersensitivity fesoterodine fumarate extended-release tablets ingredients , tolterodine tartrate tablets tolterodine tartrate extended-release capsules [ pharmacology ( 12.1 ) ] . included angioedema [ ( 5.1 ) ] . urinary retention [ ( 5.2 ) ] gastric retention [ ( 5.3 ) ] uncontrolled narrow-angle glaucoma [ ( 5.4 ) ]",
    "ingredients": [
        {
            "name": "Fesoterodine fumarate",
            "code": "EOS72165S7"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FRUCTOSE",
            "code": "6YSS42VSEV"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "organization": "Dr.Reddy's Laboratories Inc.,",
    "name": "Fesoterodine fumarate",
    "effectiveTime": "20190814",
    "indications_original": "Fesoterodine fumarate extended-release are indicated for the treatment of: • Overactive bladder(OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2)",
    "contraindications_original": "• OAB in Adults:The recommended starting dosage is 4 mg orally once daily. Based upon individual response and tolerability, increase the maximum dosage of 8 mg once daily. ( 2.1 ) • NDO in Pediatric Patients 6 Years and Older: Pediatric Patients Weighing Greater than 25 kg and up to 35 kg: The recommended dosage is 4 mg orally once daily. If needed, dosage may be increased to 8 mg orally once daily. (2.2) Pediatric Patients Weighing Greater than 35 kg: The recommended starting dosage is 4 mg orally once daily. After one week, increase to 8 mg orally once daily. (2.2) • Adult or Pediatric Patients with Renal Impairment : Refer to the full prescribing information for recommended dosage. ( 2.3 , 2.4 ) • Dosage Modifications Due to Strong CYP3A4 Inhibitors : Refer to the full prescribing information for recommended dosage. ( 2.5 ) • Administration : Swallow whole with liquid. Do not chew, divide, or crush. Take with or without food. ( 2.6 )",
    "warningsAndPrecautions_original": "Fesoterodine fumarate extended-release tablets, 4 mg are light blue colored, oval shaped, biconvex, film-coated, debossed with ‘ ’ on one side and 'FS' on the other side and are supplied in bottles of 30's, and 90’s.\n                  Bottles of 30                                       NDC 43598-247-30\n                  Bottles of 90                                       NDC 43598-247-90\n                  Fesoterodine fumarate extended-release tablets, 8 mg are blue colored, oval shaped, biconvex, film-coated, debossed with ‘ ’ on one side and ‘FT’ on the other side and are supplied in bottles of 30's, and 90’s.\n                  Bottles of 30                                       NDC 43598-248-30\n                  Bottles of 90                                       NDC 43598-248-90\n                  Store fesoterodine fumarate extended-release tablets, at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions_original": "Fesoterodine fumarate extended-release tablets are contraindicated in patients with any of the following,\n                  \n                     known or suspected hypersensitivity to fesoterodine fumarate extended-release tablets or any of its ingredients, or to tolterodine tartrate tablets or tolterodine tartrate extended-release capsules [see Clinical Pharmacology (12.1)]. \n                     Reactions have included angioedema [see Warnings and Precautions (5.1)].\n                      urinary retention [see Warnings and Precautions (5.2)] \n                     gastric retention [see Warnings and Precautions (5.3)] \n                     uncontrolled narrow-angle glaucoma [see Warnings and Precautions (5.4)]"
}